These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Knebelmann B; Ananth S; Cohen HT; Sukhatme VP Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397 [TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
5. Hypertonic activation of AE2 anion exchanger in Xenopus oocytes via NHE-mediated intracellular alkalinization. Humphreys BD; Jiang L; Chernova MN; Alper SL Am J Physiol; 1995 Jan; 268(1 Pt 1):C201-9. PubMed ID: 7840148 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344 [TBL] [Abstract][Full Text] [Related]
8. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related]
9. Down-regulated in adenoma mediates apical Cl-/HCO3- exchange in rabbit, rat, and human duodenum. Jacob P; Rossmann H; Lamprecht G; Kretz A; Neff C; Lin-Wu E; Gregor M; Groneberg DA; Kere J; Seidler U Gastroenterology; 2002 Mar; 122(3):709-24. PubMed ID: 11875004 [TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815 [TBL] [Abstract][Full Text] [Related]
11. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303 [TBL] [Abstract][Full Text] [Related]
12. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Perera AD; Kleymenova EV; Walker CL Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984 [TBL] [Abstract][Full Text] [Related]
13. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610 [TBL] [Abstract][Full Text] [Related]
15. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510 [TBL] [Abstract][Full Text] [Related]
17. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495 [TBL] [Abstract][Full Text] [Related]
18. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800 [TBL] [Abstract][Full Text] [Related]
19. The presence of NHE1 and NHE3 Na+-H+ exchangers and an apical cAMP-independent Cl- channel indicate that both absorptive and secretory functions are present in calf gall bladder epithelium. Bazzini C; Bottà G; Meyer G; Baroni MD; Paulmichl M Exp Physiol; 2001 Sep; 86(5):571-83. PubMed ID: 11571484 [TBL] [Abstract][Full Text] [Related]
20. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]